Beta Drugs Ltd. - Research Center

---

Results

• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Share holding
• Capital structures
• Ratio

Mar ' 23	Mar ' 22	Mar ' 21	Mar ' 20	Mar ' 19

Sources of funds

Owner's fund

Equity share capital

9.61

9.61

9.61

9.61

8.65

Share application money

-

-

-

-

-

Preference share capital

-

-

-

-

-

Reserves & surplus

86.64

67.85

53.80

46.83

31.95

Loan funds

Secured loans

3.73

5.15

3.89

7.42

6.43

Unsecured loans

-

-

-

-

-

Total

99.98

82.61

67.30

63.86

47.02

Uses of funds

Fixed assets

Gross block

59.19

53.54

43.01

31.67

19.06

Less : revaluation reserve

-

-

-

-

-

Less : accumulated depreciation

24.41

19.48

14.99

-

7.29

Net block

34.77

34.06

28.01

31.67

11.77

Capital work-in-progress

-

-

1.90

0.08

15.04

Investments

6.55

6.54

6.54

6.12

1.61

Net current assets

Current assets, loans & advances

92.72

70.30

49.78

44.35

36.23

Less : current liabilities & provisions

34.06

28.28

18.93

18.36

17.63

Total net current assets

58.66

42.01

30.85

26.00

18.60

Miscellaneous expenses not written

-

-

-

-

-

Total

99.98

82.61

67.30

63.86

47.02

Notes:

Book value of unquoted investments

6.55

6.54

6.54

6.12

1.61

Market value of quoted investments

-

-

-

-

-

Contingent liabilities

0.74

0.66

0.51

0.27

-

Number of equity sharesoutstanding (Lacs)

96.14

96.14

96.14

96.14

86.50